Back to results
US 2003/0152593 A1Published application
Antiviral activity of shiga toxin
AssigneeIdaho Research Foundation, Inc.
InventorsCarolyn H. Bohach, Witold A. Ferens
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeIdaho Research Foundation, Inc.
InventorsCarolyn H. Bohach, Witold A. Ferens
Estimating the term…
The present invention provides methods and compositions for eliminating virally-infected cells by administering a Shiga-toxin composition, and the present invention provides methods and compositions for suppressing bovine leukemia-related cell proliferation. In the methods, a Shiga-toxin composition is administered in an amount effective to suppress bovine leukemia-related cell proliferation. The Shiga-toxin composition can include a Shiga-toxin polypeptide; a probiotic microorganism expressing a Shiga-toxin polypeptide; or a transgenic plant expressing a Shiga-toxin polypeptide. In one embodiment, the Shiga-toxin polypeptide is Stx1A and, in another embodiment, the Shiga-toxin polypeptide is Stx1 holotoxin. In yet a further embodiment, the Shiga-toxin polypeptide comprises Stx2.
A method for eliminating virally-infected cells in a mammalian subject, comprising administering to a mammalian subject infected with a virus an amount of a Shiga-toxin composition effective to eliminate virally-infected cells.
A method for treating a virus infection in a mammal, comprising administering to a mammal infected with a virus an amount of a Shiga-toxin composition effective to treat the virus infection.
A method for suppressing bovine leukemia virus-related cell proliferation in an animal subject, comprising administering an amount of a Shiga-toxin type composition to an animal subject effective to suppress bovine leukemia virus-related cell proliferation in the animal subject, wherein the Shiga-toxin composition comprises Shiga-toxin type 2 or a Shiga-toxin type 2 variant.
A method for treating a bovine leukemia virus-related disorder in an animal subject, comprising administering to an animal subject an amount of a Shiga-toxin composition effective to suppress bovine leukemia virus-related cell proliferation in the animal subject, wherein the Shiga-toxin composition comprises Shiga-toxin type 2 or a Shiga-toxin type 2 variant.
A method for treating a cell, comprising administering to the cell an amount of a Shiga-toxin polypeptide effective to suppress bovine leukemia virus-related cell proliferation, wherein the Shiga-toxin composition comprises Shiga-toxin type 2 or a Shiga-toxin type 2 variant.
Dependencies are inferred from the claim text.